[go: up one dir, main page]

IS4466A - Composition and treatment for multiple sclerosis - Google Patents

Composition and treatment for multiple sclerosis

Info

Publication number
IS4466A
IS4466A IS4466A IS4466A IS4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A
Authority
IS
Iceland
Prior art keywords
treatment
composition
multiple sclerosis
sclerosis
Prior art date
Application number
IS4466A
Other languages
Icelandic (is)
Inventor
Smilek Dawn
Samson Michael
Gefter Malcolm
Hsu Di-Hwei
Shi Jia-Dong
Paliard Xavier
Devaux Brigitte
Rothbard Jonathan
Franzén Henry
Original Assignee
Immulogic Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corporation filed Critical Immulogic Pharmaceutical Corporation
Publication of IS4466A publication Critical patent/IS4466A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS4466A 1994-10-25 1997-04-17 Composition and treatment for multiple sclerosis IS4466A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
IS4466A true IS4466A (en) 1997-04-17

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4466A IS4466A (en) 1994-10-25 1997-04-17 Composition and treatment for multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A7 (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
WO1997035193A1 (en) 1996-03-21 1997-09-25 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
HK1039636A1 (en) * 1998-05-05 2002-05-03 科里克萨公司 Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (en) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
NZ546807A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
CA2667637C (en) 2006-10-31 2021-04-20 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
DK2488196T3 (en) 2009-10-12 2016-03-14 Lifebio Lab Llc A composition for treating multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
EP2688904B1 (en) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
HK1231425A1 (en) 2014-01-13 2017-12-22 Berg Llc Enolase 1 (eno1) compositions and uses thereof
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (en) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド Treatment of autoimmune disease by oral administration of self-antigen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
CA2070281C (en) * 1989-12-20 2005-08-23 David Allen Hafler Improved treatment of autoimmune diseases by aerosol administration of auto antigens
ES2107459T3 (en) * 1990-03-02 1997-12-01 Autoimmune Inc IMPROVEMENT OF THE REPRESSIVE REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF SELF-ANTIGENS.
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc Peptide capable of stimulating a subgroup of t-cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
CA2123228A1 (en) * 1991-11-19 1993-05-27 Bishwajit Nag Mhc subunit conjugates useful in ameliorating deleterious immune responses
EP0627933B1 (en) * 1992-02-28 2002-11-27 Autoimmune, Inc. Bystander suppression of autoimmune diseases
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
DK0863155T3 (en) * 1992-04-09 2002-05-13 Autoimmune Inc Suppression of T cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
JPH08500823A (en) * 1992-08-17 1996-01-30 オートイミューン インク Bystander suppression of retrovirus-related neurological disorders
JPH09502346A (en) * 1993-09-03 1997-03-11 イミユロジク・フアーマシユーチカル・コーポレーシヨン Use of myelin oligodendrocyte glycoprotein and its peptide moieties in protocols associated with autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
EP0752880A4 (en) * 1994-04-08 2000-08-09 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES USING ORAL TOLERANCE AND / OR INTERFERON TYPE I
EP0752879A4 (en) * 1994-04-08 1999-07-21 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
PL317197A1 (en) * 1994-05-10 1997-03-17 Immulogic Pharma Corp Compositions for and method of treating sclerosis multiplex
CA2192468A1 (en) * 1994-06-09 1995-12-14 Johannes M. Van Noort Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
DE69525544T2 (en) * 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. PEPTIDE ANALOGUE OF THE HUMAN MYELINE-BASED PROTEIN WITH SUBSTITUTION IN POSITION 91 FOR TREATING MULTIPLE Sclerosis

Also Published As

Publication number Publication date
FI971750A7 (en) 1997-06-24
SK51297A3 (en) 1998-03-04
JPH10504039A (en) 1998-04-14
NO971900D0 (en) 1997-04-24
PL324091A1 (en) 1998-05-11
HUT77047A (en) 1998-03-02
CZ122697A3 (en) 1997-09-17
NO971900L (en) 1997-06-25
WO1996012737A3 (en) 1996-10-10
EP0787147A1 (en) 1997-08-06
AU4278296A (en) 1996-05-15
WO1996012737A2 (en) 1996-05-02
CA2203629A1 (en) 1996-05-02
SI9520118A (en) 1998-08-31
BR9509438A (en) 1997-12-23
IL115766A0 (en) 1996-01-19
FI971750A0 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
IS4466A (en) Composition and treatment for multiple sclerosis
FI970859A7 (en) Metal treatment composition and process
IS4481A (en) Dihydropyramidine and their use
DE69607321D1 (en) CLEANING PROCEDURE AND COMPOSITION
NO20035726D0 (en) Benzopyran-containing compounds and process for use thereof
DE69526966D1 (en) SKIN-STRENGTHING COMETIC COMPOSITION
DE69513916D1 (en) Surface treatment composition
DK0804078T3 (en) Composition and use thereof
NO943763D0 (en) 4-arylamino-benzopyrans and related compounds
BR9506832A (en) N-pyrazolylanilines and n-pyrazolylaminopyridines
FI954773A0 (en) Anti-hypertriglyceridemia composition
DE69620642D1 (en) CLEANING PROCEDURE AND COMPOSITION
FI951060L (en) Formulations and treatment methods
KR960705557A (en) ANTIMICROBIAL METHOD AND COSMETIC COMPOSITION
DE69622461D1 (en) Surface treatment composition
BR9510062A (en) Esterified macromonome and composition
BR9509688A (en) Pharmaceutical composition and composition
IL113661A0 (en) Compositions and treatment for multiple sclerosis
DE69519913D1 (en) Perm composition
ITMI940362A0 (en) ANTICOUGH COMPOSITION
GB9415901D0 (en) Novel compounds and treatment
NO972216D0 (en) Acrotein-releasing composition and its use
GB9415900D0 (en) Novel compounds and treatment
BR9507133A (en) N-aryl and n-alkylsulfonylamines
NO952766D0 (en) Solvent compositions and methods